Method and kit for the detection of pancreatic dysfunction

A kit for the detection of pancreatic exocrine dysfunction, comprising one or more of a monoclonal antibody or a fragment thereof selected from the group consisting of

• an anti-APOA2 terminus monoclonal antibody or a fragment thereof and an anti-APOA2 non-terminus monoclonal antibody or a fragment thereof,
• wherein the anti-APOA2-ATQ terminus antibody comprises the CDRs shown in the following (i) or (ii);
• (i) in the heavy chain, CDR1, CDR2, and CDR3 having the amino acid sequence represented by SEQ ID NOs:
• 3, 4, and 5, respectively, and
• in the light chain, CDR1, CDR2, and CDR3 having the amino acid sequence represented by SEQ ID NOs:
• 6, 7, and 8, respectively, and
• (ii) in the heavy chain, CDR1, CDR2, and CDR3 having the amino acid sequence represented by SEQ ID NOs:
• 9, 10, and 11, respectively, and
• in the light chain, CDR1, CDR2, and CDR3 having the amino acid sequence represented by SEQ ID NOs:
• 12, 13, and 14, respectively, and
• wherein the anti-APOA2 non-terminus antibody comprises the CDRs shown in the following (iii) or (vi);
• (iii) in the heavy chain, CDR1, CDR2, and CDR3 having the amino acid sequence represented by SEQ ID NOs:
• 15, 16, and 17, respectively, and
• in the light chain, CDR1, CDR2, and CDR3 having the amino acid sequence represented by SEQ ID NOs:
• 18, 19, and 20, respectively, and
• (vi) in the heavy chain, CDR1, CDR2, and CDR3 having the amino acid sequence represented by SEQ ID NOs:
• 21, 22, and 23, respectively, and
• in the light chain, CDR1, CDR2, and CDR3 having the amino acid sequence represented by SEQ ID NOs:
• 24, 25, and 26, respectively.